Skip to Content

HubMed©Preclinical: Adam 



HubMed©Preclinical- named Adam- is a suite composed of specialized modules, each tailored to address a critical phase of the stages in preclinical process:

  • Molecule Screening: This module enables rapid and intelligent screening of molecular candidates, helping researchers identify promising compounds early in the process.

  • Receptorial Analysis: HubMed provides sophisticated tools for analyzing how candidate molecules interact with biological receptors, supporting more targeted and effective product development.

  • Toxicological Analysis: Ensuring safety is paramount. This module streamlines toxicological assessments, allowing teams to evaluate potential risks efficiently and comply with regulatory standards. 

Adam Basic 

This solution enables rapid and intelligent screening of molecular candidates, helping R&D teams to identify promising compounds early in the process. By tackling the most complex challenges in modern drug development, Adam basic streamlines the identification, validation, and optimization of therapeutic candidates—dramatically reducing development timelines and delivering superior research outcomes. It is a module addressing the first and most critical step in early drug discovery: identifying the optimal biological target for treating or preventing a disease. 

Adam basic leverages state‑of‑the‑art artificial intelligence and advanced machine learning models to rapidly and accurately evaluate a broad spectrum of critical properties in potential drug candidates. By integrating predictive analytics, deep molecular intelligence, and automated data interpretation, the platform delivers fast, high‑confidence insights across complex chemical spaces.

The solution empowers research teams with AI‑driven, in‑depth assessments of molecular behavior, safety, and performance early in the discovery pipeline—enabling smarter, data‑backed decisions when they matter most. 

Adam’s intelligent analysis reduces uncertainty, prioritizes the most promising compounds, and minimizes costly late‑stage failures.

By accelerating lead identification and optimizing candidate selection, the Medea Solution significantly enhances the efficiency and success rate of drug discovery programs. The result is a faster, more informed path to developing innovative, high‑impact therapies driven by actionable AI insights.


Adam Advanced 

Adam Advanced Solution includes either the Molecule Screeing Module and the Receptorial and Toxicological Analysis ones: it provides sophisticated tools also for analyzing how candidate molecules interact with biological receptors; besides this it also support R&D Teams  with toxicological assessments, allowing them to evaluate potential risks efficiently and comply with regulatory framework. 

Even the most brilliant scientists work with limited time and resources. HubMed©Advanced gives R&D teams a view of all scientific information — surfacing key connections that manual approaches cannot do. Three-dimensional visualizations of its high-precision knowledge graph make target-disease relationships clearer so prioritization decisions are much more informed.

Pricing

 

Preclinical research encompasses the early phases of drug discovery, from target identification to the nomination of a preclinical candidate and extends to later stages that include safety and toxicology studies, process scale-up, and pharmaceutical development.

By employing advanced AI algorithms, Adam guides users through hit refinement, chemical optimization, and safety profiling, ensuring candidate molecules meet stringent efficacy, pharmacokinetics, and developability criteria. The module supports iterative cycles of in vitro and in vivo testing, seamlessly integrating multidisciplinary expertise from medicinal chemistry, pharmacology, and toxicology.